AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematologic NeoplasmsGraft vs Leukemia EffectGraft vs Tumor EffectTissue DonorsTransplantation, AutologousLeukemiaRetrospective StudiesTreatment OutcomeBone Marrow TransplantationRecurrenceBlood DonorsAcute DiseaseLiving DonorsTime FactorsSurvival RateFollow-Up StudiesRisk FactorsProspective StudiesGraft SurvivalHistocompatibility TestingTransplantation ChimeraIsoantigensT-LymphocytesHistocompatibilityLymphocyte Culture Test, MixedWhole-Body IrradiationStem Cell TransplantationTransplantation, IsogeneicGraft RejectionBusulfanTransplantation ImmunologySkin TransplantationMyeloablative AgonistsImmunosuppressive AgentsGraft vs Host ReactionChimerismLymphocyte DepletionLymphocyte ActivationImmunosuppressionVidarabineHLA AntigensPeripheral Blood Stem Cell TransplantationLeukemia, Myeloid, AcuteMice, Inbred C57BLRemission InductionMice, Inbred BALB CLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCytomegalovirus InfectionsLeukocyte TransfusionAnemia, AplasticPrecursor Cell Lymphoblastic Leukemia-LymphomaCytotoxicity, ImmunologicHematologic DiseasesSurvival AnalysisSpleenRadiation ChimeraMyelodysplastic SyndromesTransplantation ToleranceAntilymphocyte SerumSiblingsBlood Transfusion, AutologousHepatic Veno-Occlusive DiseaseDendritic CellsImmune ToleranceT-Lymphocytes, CytotoxicLymphocytesBlood TransfusionCord Blood Stem Cell TransplantationFlow CytometryCD4-Positive T-LymphocytesMinor Histocompatibility AntigensCyclophosphamideKiller Cells, NaturalMice, Inbred StrainsHistocompatibility AntigensCombined Modality TherapyImmunotherapy, AdoptiveCD8-Positive T-LymphocytesCells, CulturedTissue and Organ ProcurementMice, Inbred C3HCytomegalovirusLeukemia, MyeloidCyclosporineT-Lymphocytes, RegulatoryImmunophenotypingChimeraMycosesH-2 AntigensCytotoxicity Tests, ImmunologicThymus GlandAntigens, CDIsoantibodiesGraft Enhancement, ImmunologicAntibodies, MonoclonalLiver Transplantation
TransplantationGVHDLymphocyte infusionGraftHematologicalUnderwentUmbilical cordAutologous and allogeneicHuman leukocyCurative treatmentLymphomaRelapseHematopoietic Cell TransplantBoneMortalityAntigensInfusionComplicationPeripheral blood stem cellsAcuteEngraftmentCarries significant risksPatient'sTransplantsHematologicHaploidenticalMalignantComplicationsStem-cellMatched unrelated donorPosttransplantHSCTsSurvivalChimerismImmunosuppressionRecipients and donorsTreatmentUnmetSuitable donorCellsSickle cell diSignificantly
Transplantation69
GVHD28
  • GVHD occurs when donor immune cells recognize and attack host antigens. (medscape.com)
  • Many factors affect the balance between a graft-versus-tumor effect and GVHD, including genetic differences between donor and host and the magnitude of the T-cell response. (medscape.com)
  • The incidence of GVHD can be as high as 40-60% of patients receiving HSCT. (medscape.com)
  • Boy who developed stage 3 skin involvement with acute graft versus host disease (GVHD) despite receiving prophylaxis with cyclosporin A. The donor was a sister matched for human leukocyte antigen. (medscape.com)
  • Waller notes that GvHD is a serious risk for anyone who receives a donor transplant. (emory.edu)
  • GvHD is an immune reaction of donor T cells against normal tissues in the transplant recipient," he says. (emory.edu)
  • Orca-T combines purified cells from a matched donor to replace a patient's diseased blood and immune system with a healthy one while lowering their risk of developing GvHD and other life-threatening transplant-related side effects. (emory.edu)
  • 1 The study enrolled 333 patients who were randomly assigned in a 1:1 ratio to one of two treatment groups receiving either an intravenous infusion of vedolizumab 300 mg or placebo on days -1 (before allo-HSCT), and on days +13, +41, +69, +97, +125, and +153 following allo-HSCT, alongside a background GvHD prophylaxis regimen. (businesswire.com)
  • A team of hematology marrow transplant department of the Saint-Louis Hospital AP-HP, the Paris University and INSERM (U976 unit) in collaboration with the Pasteur Institute, led the work on graft against host disease (GVHD) using liquid chromatography coupled with mass spectrometry to study the metabolome of allogeneic patients at Saint-Louis hospital AP-HP. (pasteur.fr)
  • Graft against the host (GVHD) is a major complication that may occur after a allograft, and is characterized by tissue damage induced by donor immune cells which react against those of the recipient. (pasteur.fr)
  • Indoles derivatives are ligands of the receptor Aryl Hydrocarbon (AhR), which regulates the activation and differentiation of immune cells and could therefore contribute to limiting the risk of immune reaction to allogeneic origin of GVHD. (pasteur.fr)
  • Treatment focuses on blocking the expansion of donor T cells, as GVHD develops from the expansion of these cells. (oncologynurseadvisor.com)
  • Recent studies are investigating the efficacy of rituximab (Rituxan) for GVHD in pediatric HSCT patients. (oncologynurseadvisor.com)
  • Despite a huge progress in HSCT techniques and posttransplant care, GVHD remains a significant obstacle in successful HSCT outcome. (hindawi.com)
  • GVHD occurs in about 30-50% and 70% of recipients allografted from matched related and matched unrelated donors, respectively [ 1 ]. (hindawi.com)
  • The degree of HLA disparity between donor and recipient is a well-known and widely accepted independent risk factor for GVHD development [ 2 ]. (hindawi.com)
  • Inherited genetic variants such as single-nucleotide polymorphisms (SNPs) of candidate genes, encoding various cytokines, chemokines, and inflammatory regulators, have become a subject of interest of genetic studies searching for independent predictors of GVHD development and HSCT outcome [ 4 - 7 ]. (hindawi.com)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • Our primary aim is to improve donor lymphocyte therapy to the point that the occurrence of GvHD can be practically ruled out. (uni-mainz.de)
  • However, this practice is believed to increase morbidity and mortality related to graft-versus-host disease (GVHD) in which T-cells from the donor turn against the recipient's epithelial cells- mainly skin, liver and gastrointestinal tract cells. (biocodexmicrobiotainstitute.com)
  • Second, the use of the patient's own bone marrow cells for gene replacement does not result in graft-versus-host disease (GVHD), a major complication of current allogeneic transplant. (nih.gov)
  • HSCT patients are presumed immunocompetent if they are at least 24 months post-HSCT, are not receiving immunosuppressive therapy, and do not have graft- versus-host disease (GVHD). (cdc.gov)
  • Allogeneic HSCT carries significant risks such as rejection of the graft, infection, graft versus host disease (GVHD), and potential long-term side effects, translating into a 50% morbidity and mortality rate at 3 years post HSCT. (smart-immune.com)
  • However, graft-versus-host disease (GVHD) is a very serious complication and a major cause of morbidity and mortality after allogeneic HSCT. (lidsen.com)
  • Graft-versus-host disease (GVHD) is a serious complication that may occur in patients receiving allogeneic hematopoietic stem cell transplant (HSCT). (lidsen.com)
  • Graft-versus-host disease (GVHD) and infections are the major obstacles of HSCT, and their close relationship has been suggested. (ashpublications.org)
  • Discrepancies across studies referring to various graft sources, donor types, conditioning regimens, and the use of immunomodulators complicate interpretations of the clinical outcomes of ABOi-HSCT, such as transfusion requirements, graft-versus-host disease (GVHD), disease relapse, overall survival (OS), and non-relapse mortality (NRM). (blood-genomics.com)
Lymphocyte infusion1
  • Prior allogeneic hematopoietic stem cell transplant (HSCT) or donor lymphocyte infusion within 6 months prior to enrollment, current acute graft versus host disease grade 2-4 by Glucksberg criteria or severity B-D by by International Bone Marrow Transplant Registry (IBMTR) index or history of severe (grade 3-4) acute graft versus host disease. (moffitt.org)
Graft10
  • Infection and graft-versus-host disease are major complications of allogeneic HSCT. (wikipedia.org)
  • Also, the incidence of patients experiencing rejection is very rare (and graft-versus-host disease impossible) due to the donor and recipient being the same individual. (wikipedia.org)
  • In allogeneic HSCT, donor T cells target malignant hematopoietic cell populations, creating a graft-versus-tumor effect. (medscape.com)
  • Principal investigator Edmund K. Waller, MD, PhD, FACP, says the net result of giving the patient a precise number of donor T cells with specific functions "leads to better elimination of cancer with less graft versus host disease and less toxicity from the transplant. (emory.edu)
  • To create the precision-engineered donor graft, Waller explains that different cellular subsets in the graft are selectively purified and then infused into the transplant recipient in a timed fashion. (emory.edu)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • The other three allogeneic recipients died from either graft-vs-hostdisease, relapse, or acetaminophen-induced hepatic necrosis. (cancernetwork.com)
  • The superior clinical outcomes of allogeneic SCT versus chemotherapy alone as post-remission treatment could be related to the graft-versus-leukemia (GVL) effects of recovered donor T cells. (biomedcentral.com)
  • This life-threatening disorder develops when donor (graft) immune cells cause inflammatory damage to recipient (host) tissues. (lidsen.com)
  • Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. (cdc.gov)
Hematological4
  • The Phase 3, randomized, double-blind, placebo-controlled, multicenter GRAPHITE study evaluated the efficacy and safety of vedolizumab as prophylaxis for intestinal aGvHD in patients undergoing allo-HSCT from unrelated donors for the treatment of hematological malignancies. (businesswire.com)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • We are evaluating whether allogeneic HSCT can reconstitute normal hematopoiesis in MonoMAC and reverse the hematological abnormalities in MDS, if MDS is present at the time of transplant. (nih.gov)
  • In this review, we summarized literature of the impact of ABO incompatibility on post-HSCT outcomes and outlined important immune-mediated hematological events. (blood-genomics.com)
Underwent5
  • The final sample consisted of 35 records patients aged between 2 and 18 years old who underwent HSCT from February 2008 to December 2015 and who presented the data necessary for the study. (bvsalud.org)
  • however, patients who achieved hematologic complete remission (HCR) following consolidation therapy who had an appropriate donor underwent allo-HSCT during consolidation. (cancertherapyadvisor.com)
  • Of the 58 patients who underwent allo-HSCT, 75.9% had achieved MCR prior to allo-HSCT. (cancertherapyadvisor.com)
  • Of the 58 (74.4%) patients who underwent allo-HSCT, the rates of relapse, relapse mortality, and transplant-related relapse mortality were 15.5%, 8.6%, and 10.3%, respectively. (cancertherapyadvisor.com)
  • For the study, the investigators conducted a retrospective analysis of clinical data from patients who underwent a HSCT between January 2010 and December 2016 at the Salvador Zubirán National Institute of Health Sciences and Nutrition. (contagionlive.com)
Umbilical cord1
  • Other donor cells can come from unrelated match donors, partially matched or half-matched family members, or in some circumstances, from an umbilical cord blood donor. (reachmd.com)
Autologous and allogeneic2
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • Haematopoietic stem cell transplants have been performed in more than 1 500 000 patients (both autologous and allogeneic) to date.1 Although haematological cancers remain the main indication, haematopoietic stem cell transplants are increasingly considered in the treatment of non-malignant disorders and genetic diseases such as haemoglobinopathies (sickle cell anaemia, thalassaemia) that can benefit greatly from this type of transplant. (who.int)
Human leukocy1
  • Allogeneic HSCT uses human leukocyte antigen (HLA)-matched stem cells derived from a donor. (emory.edu)
Curative treatment2
  • Allogeneic hematopoietic stem cell (HSC) is a curative treatment used for many hematologic malignancies and congenital or acquired anomalies of hematopoiesis. (pasteur.fr)
  • While allogeneic HSCT is the conventional curative treatment for immunodeficiency and MDS, patients with MonoMAC, because of an intact T-cell population and co-existing infection, represent a profile not generally encountered in the setting of allogeneic HSCT. (nih.gov)
Lymphoma3
  • These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. (wikipedia.org)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
Relapse4
  • For other cancers such as acute myeloid leukemia, though, the reduced mortality of the autogenous relative to allogeneic HSCT may be outweighed by an increased likelihood of cancer relapse and related mortality, so the allogeneic treatment may be preferred for those conditions. (wikipedia.org)
  • While the standard-of-care in Japan for the treatment of younger patients with newly diagnosed Ph+ ALL is allo-HSCT preceded by imatinib plus intensive chemotherapy induction therapy, 30% to 40% of patients treated with this regimen in clinical trials were unable to undergo allo-HSCT due to older age, early relapse, or therapy-related death. (cancertherapyadvisor.com)
  • Secondary study endpoints included HCR, safety, and the efficacy of allo-HSCT (ie, relapse-free survival, relapse rate, and non-relapse mortality). (cancertherapyadvisor.com)
  • Allo-hSCT is estimated to reduce the risk of leukemia relapse to half, but with significant risk for treatment-related complications. (cancercentrum.se)
Hematopoietic Cell Transplant1
  • Lower GI aGvHD represents a critical unmet need in patients undergoing allo-HSCT," said Yi-Bin Chen, MD, Director, Hematopoietic Cell Transplant & Cell Therapy Program, Mass General Cancer Center. (businesswire.com)
Bone5
  • Eligibility includes having developed cytopenias (reduced blood cell counts) and not having an HLA-identical matched sibling donor for bone marrow transplant (BMT). (fanconi.org)
  • The blood cells are harvested from the donor and stored, and then the sickle cell disease patient is given high doses of chemotherapy to get rid of all the remaining blood cells in the bone marrow in order for them to be able to receive the healthy donated cells. (reachmd.com)
  • Further, the HSCT was peripheral blood in 83 patients, bone marrow in 21, and primed-bone marrow in 21 patients. (contagionlive.com)
  • First, the use of autologous hematopoietic stem cells for gene therapy obviates the need for a matched bone marrow donor since each individual would serve as his or her own bone marrow stem cell donor. (nih.gov)
  • This lets the cells of the donor go into the bone marrow and produce normal immune cells. (zhihuiya.com)
Mortality1
  • Despite such a progress, HSCT is still associated with substantial transplant-related mortality (TRM). (hindawi.com)
Antigens6
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • The concept of allogeneic HSCT is pivoted on compatibility of HLA antigens between the patient and the donor which are inherited from parents and passed on to the off-springs. (narayanahealth.org)
  • An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. (lookformedical.com)
  • Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. (lookformedical.com)
  • Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (lookformedical.com)
  • Isohemagglutinins (ISO) targeting red blood cell (RBC) antigens are associated with post-HSCT immunohematological complications, including hemolysis, passenger lymphocyte syndrome (PLS), and pure red cell aplasia (PRCA). (blood-genomics.com)
Infusion5
  • RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant. (bioseek.eu)
  • To assess the clinical efficacy donor NK cell infusion, in terms of tumor response, response duration, and survival, in patients with progressive or recurrent malignant disorders. (bioseek.eu)
  • Phase I: Patients receive an infusion of donor natural killer (NK) cells on days 18 and 21. (bioseek.eu)
  • Phase II: Patients receive an infusion of donor NK cells on days 14 and 21. (bioseek.eu)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
Complication1
  • 1 Intestinal aGvHD is a serious complication characterized by inflammation of the GI tract which can affect patients undergoing allo-HSCT, a common treatment for blood cancers. (businesswire.com)
Peripheral blood stem cells1
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
Acute1
  • Winship is one of several clinical trial sites for the Precision-T study evaluating the safety and efficacy of Orca-T, a cell therapy that combines purified cells from a matched donor, in patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and high-risk myelodysplastic sydromes (MDS). (emory.edu)
Engraftment2
  • with the establishment of a full donor lymphoid engraftment, we eliminate the risk of kidney rejection and the need of lifelong immunosuppression. (ca.gov)
  • The biological questions with MonoMAC center around whether the individual leukocyte compartments that are lost in MonoMAC (B-lymphocytes, NK cells, and monocytes) will be constituted with HSCT, and whether the residual recipient T-lymphocytes will represent an impediment to engraftment. (nih.gov)
Carries significant risks1
  • According to Ivan Dimov, PhD, cofounder and chief executive officer of Orca Bio, the Menlo Park, Calif.-based biotechnology company behind Orca-T, "The Precision-T study is an important step forward for patients battling deadly blood cancers like AML and ALL, which are often aggressive and for which standard allo-HSCT treatment carries significant risks. (emory.edu)
Patient's2
  • It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). (wikipedia.org)
  • In the allogeneic stem cell technique, what happens is that the leukemia patient's own hematopoietic cells are first destroyed by chemotherapy and radiation therapy. (uni-mainz.de)
Transplants1
  • Allogeneic transplants involve grafts from a genetically nonidentical donor of the same species and are the transplant type most often used in children. (oncologynurseadvisor.com)
Hematologic1
  • GRAPHITE (vedolizumab-3035) is a randomized, double-blind, placebo controlled study designed to evaluate the use of vedolizumab as prophylaxis of intestinal aGvHD in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder from an unrelated donor. (businesswire.com)
Haploidentical1
  • 1. By using haploidentical parents, we will expand the number of potential living donors, and 2. (ca.gov)
Malignant1
Complications1
  • Despite the improvement in the management of patients, allogeneic HSCT remains associated with severe immunological complications. (pasteur.fr)
Stem-cell8
  • ECIL-6 guidelines recommend quantitative PCR of whole blood, plasma, or serum to screen for EBV DNA in allogeneic hematopoietic stem cell transplant (HSCT) recipients and to monitor EBV DNA-emia. (medscape.com)
  • Previous to the approval of Skysona, there was no FDA-approved therapy, however standard-of-care therapy for CALD is allogeneic hematopoietic stem cell transplant (allo-HSCT), the place the affected person receives stem cells from a donor. (neswblogs.com)
  • Antibiotic prophylaxis prior to an allogeneic hematopoietic stem cell (HSC) transplant is common practice in hematology-oncology. (biocodexmicrobiotainstitute.com)
  • thus, the eligibility of stem-cell donors with CHIP is questionable. (bvsalud.org)
  • METHODS: We collected blood samples from 500 healthy, related HSCT donors (age ≥ 55 years) at the time of stem-cell donation for targeted sequencing with a 66-gene panel. (bvsalud.org)
  • Immunocompromised patients who have received a hematopoietic stem cell transplant (HSCT) have an incidence of active tuberculosis infection that is 10 to 40 times higher than the general population. (contagionlive.com)
  • PURPOSE: This phase I/II trial is studying the side effects and best dose of donor natural killer cells when given after a donor stem cell transplant in treating patients with advanced cancer. (bioseek.eu)
  • Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. (cdc.gov)
Matched unrelated donor2
  • Four patients were alive withno evidence of disease (three matched unrelated donor and one matched relateddonor). (cancernetwork.com)
  • On the day before the BMT, patients in the matched unrelated donor group also receive a low-dose of whole-body radiation. (zhihuiya.com)
Posttransplant1
  • Reaction to a TCZ plus posttransplant cyclophosphamide (PTCY) consolidation therapy in the allogeneic-HSCT-associated sCRS group yielded significantly inferior long-term outcome as compared to TCZ-based therapy in the COVID-19-associated group ( P = 0.003). (akjournals.com)
HSCTs2
  • Data of 58 113 HSCTs (allogeneic: 63% vs autologous: 37%) performed between 1986 and 2006 by 432 transplant teams were collected. (nus.edu.sg)
  • The increase in allogeneic HSCTs is greater than in autologous HSCTs. (nus.edu.sg)
Survival5
  • OSAKA, Japan & CAMBRIDGE, Mass.--( BUSINESS WIRE )--Takeda ( TSE:4502/NYSE:TAK ) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo. (businesswire.com)
  • Thus, indeed with a critical rate of blended chimerism, HSCT gives considerable advantage to WAS patients, with amazing by and large survival [ 2 ]. (alliedacademies.org)
  • In their concluding remarks, the study authors noted that "this study demonstrated [dasatinib]-combined 2-step induction improved pretransplant treatment, which facilitated [allo-HSCT] and resulted in significantly improved survival. (cancertherapyadvisor.com)
  • Immunosuppression before and after allogeneic transplant has been found to dramatically improve allograft survival and, despite side effects, has been a mainstay of patient management. (lidsen.com)
  • Calcineurin inhibitors, such as cyclosporine, are widely used to enhance the survival of patients who have undergone HSCT. (lidsen.com)
Chimerism2
  • Be that as it may, indeed after completely myeloablative preparative regimens, mixed donor chimerism may be a potential concern. (alliedacademies.org)
  • We are also evaluating whether we achieve sufficient donor chimerism to reverse the MDS. (nih.gov)
Immunosuppression1
  • Sequential same donor αβdepleted-HSCT/KT can 1) eliminate the need for lifelong immunosuppression, 2) reduce the need for a 2nd KT, and 3) cure the underlying disease, resulting in improved lives of patients, decreased societal costs and enormous socio-economic benefit to California. (ca.gov)
Recipients and donors2
  • In a new study, a team of investigators from Mexico set out to determine the presence and incidence of both latent and active tuberculosis in recipients and donors living in Mexico, a nation where tuberculosis is endemic. (contagionlive.com)
  • The leukemogenesis of DCL is not well understood due to the limited numbers of cases reported and lack of detailed molecular genetic information from recipients and donors. (lidsen.com)
Treatment6
  • Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • During the year before HSCT, he had received voriconazole for possible recurrent aspergillosis until 2 cavitary necrotic pulmonary lesions prompted prolonged combined treatment with caspofungin. (cdc.gov)
  • Effective prevention of aGvHD, especially with lower intestinal involvement, has been an important treatment goal for physicians when patients are undergoing allo-HSCT. (businesswire.com)
  • however, if there is no suitable donor available, antithymocyte globulin (ATG) has been used in the treatment of aplastic anemia with considerable success. (medscape.com)
  • Our multi-cytokine expression data indicate that the pathophysiology of allogeneic-HSCT and COVID-19-associated sCRS are similar therefore the same clinical grading system and TCZ-based treatment approaches can be applied. (akjournals.com)
  • Successfully transplanting cells and organs from a donor into an immunologically disparate recipient is one of the greatest treatment advances in the history of medicine. (lidsen.com)
Unmet1
  • Given challenges discovering an acceptable donor and toxicity related to allo-HSCT, there's a substantial unmet medical want for boys with CALD. (neswblogs.com)
Suitable donor1
  • The first thing you need to do is to identify a suitable donor, and that's most commonly an HLA identical sibling. (reachmd.com)
Cells14
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • It can occur in any transplant of blood cells from a donor to a patient and can be very dangerous. (emory.edu)
  • Donor T-cells proliferate and inflammatory mediators are recruited. (oncologynurseadvisor.com)
  • 2.5 years after stopping ART, in other cases, it was insufficient without protection of engrafting cells afforded by CCR5-deficiency, as CCR5-tropic virus spread to donor CD4 + T cells despite full ART suppression. (nih.gov)
  • Well, it's transplanting blood stem cells from a donor without sickle cell disease into a recipient who does have sickle cell disease. (reachmd.com)
  • The cells from the donor which are healthy are then infused into the sickle cell patient through a simple IV. (reachmd.com)
  • And if a full sibling match can't be found, it's also possible to transplant hematopoietic stem cells from a donor who's only a half match. (reachmd.com)
  • To determine the maximum number of donor NK cells that can be safely given to these patients. (bioseek.eu)
  • We initially search a potential donor within the siblings of the patient by determining HLA type, true genetic identity card of the cells. (longdom.org)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • T-cell therapies can be manufactured from different materials (mature T-cells, stem cells, possibly induced pluripotent stem cells) and from different sources (the patient or a donor). (smart-immune.com)
  • This happens when the cells of the donor attacks different parts of the patient s body. (zhihuiya.com)
  • This will further improve the chances that the patients body will accept the donor cells. (zhihuiya.com)
  • Patients will get the donor stem cells through an intravenous (IV) line that goes into a vein in their body. (zhihuiya.com)
Sickle cell di2
  • But unfortunately, only about 20% of patients with sickle cell disease in the United States have a matched donor. (reachmd.com)
  • The main requirement for a donor is to not have sickle cell disease or infection, such as HIV or hepatitis C. But what's important to know is that it's perfectly fine for the donor to have sickle cell trait. (reachmd.com)
Significantly1
  • Smart Immune's ProTcell platform is designed to reconstitute a T-cell compartment in around three months , compared with 12-18 months through the standard HSCT approach, significantly reducing the time to full immune recovery and possibly opening access to allogeneic medicine to more patients. (smart-immune.com)